Ex vivo organ treatment with peg-phospholipid molecules

Abstract

An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammationand reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient.

Description

technical field [0001] The present invention relates generally to isolated organ treatments, and in particular to such isolated organ treatments capable of inhibiting or preventing thrombotic inflammation and hypotension induced by organ reperfusion. Background technique [0002] Ischemia-reperfusion (I / R) injury (IRI) is a major contributor to the pathology of a variety of conditions, including transplantation, thrombotic disorders, sepsis, and cardiopulmonary bypass, all of which induce thrombotic inflammation. [0003] Kidney transplantation is by far the most effective treatment for patients with end-stage renal disease. Despite a dramatic improvement in treatment outcomes compared to its introduction in the 1960s, there is still 25% graft loss after 5 years and almost 50% graft loss after 10 years. The main goal for improving kidney transplantation outcomes is IRI, as IRI causes acute renal failure, delayed graft function, and distal organ failure. Immunosuppression d...

AI Technical Summary

Problems solved by technology

However, this phenomenon has also been observed in kidney and pancreas transplant recipients, who often suffer from hemodynamic instability immediately after reperfusion

Thus, a rapid decrease in systemic arterial pressure results in impaired graft perfusion and prolonged graft warm ischemia

These patients may suffer from delayed graft function, increased risk of rejection, and premature graft loss

Images